Rubicon Research Limited — Q1FY27 earnings call summary

Filed 19 August 2026 · Official transcript

Q1 FY27 revenue INR534 Cr +51% y-y; EBITDA INR131 Cr +65% y-y; PAT INR85 Cr +95% y-y
EBITDA margin guided upwards to 23% for FY27 from earlier 22-23%
Gross margin improved sequentially by 140 bps to 67.7% despite input cost rise
R&D spend at 10.9% of revenue; productivity at 5.5x; INR500 Cr spend guidance on track
Pithampur facility FDA approved; ramp-up expected from Q1 CY27; significant expansion headroom
Arinna acquisition contributed INR12 Cr revenue; EBITDA impact immaterial
US manufacturing facility acquisition strategic; commercial operations to start CY27
Management change: CFO Nitin Jajodia to Chief Commercial Officer; Rohit appointed CFO designate